Evidence map›Paper›PMID 28103725›Full record

ArticleLeukemia & lymphoma2017

A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma.

Beata Holkova, Victor Yazbeck, Maciej Kmieciak, Prithviraj Bose, Shuo Ma, Amy Kimball, Mary Beth Tombes, Ellen Shrader, Wen Wan, Caryn Weir-Wiggins and 7 more

Registry-linked trialAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia & lymphoma, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00963274 (Phase I Study of Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma or Cutaneous T-Cell Lymphoma), which is not on this map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00963274 phase1completednot on this map

Phase I Study of Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma or Cutaneous T-Cell Lymphoma

TypeinterventionalSponsorVirginia Commonwealth UniversityRan2010 to 2018Enrolled18ConditionsLeukemia, LymphomaArmsBortezomib, Romidepsin
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 25 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Novel agents for chronic lymphocytic leukemia.Journal of hematology & oncology · 2013
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Beata Holkovaa Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA.
Victor Yazbecka Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA.
Maciej Kmieciaka Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA.
Prithviraj Bosea Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA.
Shuo Mac Division of Hematology and Oncology , Robert H. Lurie Comprehensive Cancer Center, Northwestern University , Chicago , IL , USA.
Amy Kimballd Marlene and Stewart Greenebaum Cancer Center, University of Maryland , Baltimore , MD , USA.
Mary Beth Tombesa Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA.
Ellen Shradera Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA.
Wen Wane Department of Statistics , Virginia Commonwealth University , Richmond , VA , USA.
Caryn Weir-Wigginsa Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA.
Amanda Singha Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA.
Kevin T Hogana Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA.
Sarah Coninea Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA.
Heidi Sankalaa Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA.
John D Robertsa Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA.
Thomas C Sheaf Department of Hematology/Oncology , Lineberger Comprehensive Cancer Center, University of North Carolina , Chapel Hill , NC , USA.
Steven Granta Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA.
Virginia Commonwealth University · USNorthwestern University · USUNC Lineberger Comprehensive Cancer CenterUniversity of Maryland, Baltimore · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Virus Vector Shared ResourceP30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Kim Felder Rhoads · 1985 to 2026
$51.0M
X-LINKED HYPOPHOSPHATEMIAM01RR000065 · NCRR · VIRGINIA COMMONWEALTH UNIVERSITY · PI NESTLER, JOHN E · 1985 to 2010
$24.8M
P4 -TARGETING MULTIPLE MYELOMA BY COMBINING CDK INHIBITORS AND BCL-2 ANTAGONISTSP50CA142509 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KWAK, LARRY W · 2010 to 2014
$11.1M
Targeting AML with PI3K/AKT inhibitors and BH3-mimeticsR01CA167708 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI GRANT, STEVEN · 2013 to 2017
$1.6M
Targeting Multiple Myeloma with Smac-mimetics and HDAC InhibitorsR01CA205607 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI GRANT, STEVEN · 2016 to 2020
$1.6M
Phase I Trial of Bortezomib and Romidepsin in CLL and Small Cell LymphomaR21CA137823 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI GRANT, STEVEN · 2009 to 2010
$537k
NCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA016059NCI NIH HHS P50 CA142509NCI NIH HHS R01 CA167708NCI NIH HHS R01 CA205607NCI NIH HHS R21 CA137823NCRR NIH HHS M01 RR000065
6 · The paper itself

Abstract

A phase 1 study was conducted to determine the dose-limiting toxicities and maximum-tolerated dose (MTD) for bortezomib followed by romidepsin on days 1, 8, and 15 in patients with relapsed/refractory CLL/SLL or B- or T-cell lymphoma. Eighteen treated patients were evaluable for response. The MTD was 1.3 mg/m

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBortezomibCombined Modality TherapyDepsipeptidesFemaleHumansLeukemia, Lymphocytic, Chronic, B-CellLymphoma, T-Cell, CutaneousLymphoma, T-Cell, PeripheralMaleMaximum Tolerated DoseTreatment OutcomeBortezomibDepsipeptidesromidepsinBortezomiblymphomaphase 1 clinical trialromidepsin

Identifiers

PMID28103725
PMCPMC5817887
OpenAlexW2577930388

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.